We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CSTL market cap is 590.61M. The company's latest EPS is USD -2.0935 and P/E is -10.06.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.04M | 50.14M | 61.49M | 66.12M | 72.97M |
| Operating Income | -31.52M | -21.16M | -9.64M | -5.66M | -5.47M |
| Net Income | -29.2M | -18.78M | -6.91M | -2.58M | -2.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 51.87M | 64.53M | 94.09M | 155.33M | 219.79M |
| Operating Income | 7.33M | -6.54M | -40.08M | -72.86M | -67.98M |
| Net Income | 2.99M | -10.28M | -31.29M | -67.14M | -57.47M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 426.89M | 425.4M | 436.02M | 453.34M | 458.51M |
| Total Liabilities | 41.74M | 46.63M | 50.24M | 62.07M | 56.05M |
| Total Equity | 385.15M | 378.77M | 385.78M | 391.27M | 402.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 119.75M | 439.33M | 462.57M | 447.33M | 453.34M |
| Total Liabilities | 34.63M | 23.64M | 50.83M | 48.18M | 62.07M |
| Total Equity | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.44M | -29.23M | -24.21M | -5.63M | -6.84M |
| Investing | 16.58M | 1.2M | -8.51M | -16.18M | -19.7M |
| Financing | 728k | 954k | 999k | -2.3M | 10.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 7.02M | 9.87M | -18.98M | -41.66M | -5.63M |
| Investing | -937k | -4.75M | -66.66M | -166.55M | -16.18M |
| Financing | 88.29M | 305.89M | 5.42M | 1.52M | -2.3M |
| Market Cap | 590.61M |
| Price to Earnings Ratio | -10.06 |
| Price to Sales Ratio | 2.63 |
| Price to Cash Ratio | 5.85 |
| Price to Book Ratio | 1.48 |
| Dividend Yield | - |
| Shares Outstanding | 27.45M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 1.3 (6%) |
| Company Name | Castle Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.castlebiosciences.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
